Yaqrit

Yaqrit Limited is a clinical-stage life sciences company focused on developing innovative treatments for liver disease, particularly advanced conditions such as cirrhosis and its complications, as well as non-alcoholic steatohepatitis (NASH) and non-alcoholic fatty liver disease (NAFLD). With over 650 million individuals worldwide affected by chronic liver disease and associated economic costs exceeding €15.8 billion annually, Yaqrit aims to address the limited treatment options currently available, which primarily consist of antibiotics, laxatives, and liver transplants. The company combines technical expertise with clinical trial design and execution, leveraging a global network of collaborators to expedite the development of its treatment programs. By focusing on preventing, treating, and potentially reversing advanced liver disease, Yaqrit seeks to significantly improve patient outcomes and transform the lives of those suffering from these serious health conditions.